Sanofi (SNY)
(Delayed Data from NSDQ)
$51.26 USD
-1.59 (-3.01%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $51.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.26 USD
-1.59 (-3.01%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $51.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.
BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.
ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.
Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.
Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised
by Zacks Equity Research
Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.
AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.
Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.
Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
by Zacks Equity Research
Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.
Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
by Zacks Equity Research
Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.
Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Merck's Biosimilar Insulin Gets Tentative FDA Approval
by Zacks Equity Research
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
by Arpita Dutt
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt
by Zacks Equity Research
Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Perrigo Company Gets FDA Approval for Generic Topical Gel
by Zacks Equity Research
Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.
Early Read on the Q2 Earnings Season
by Sheraz Mian
I am reasonably confident that we are on our way for another reassuring earnings read.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses
by Swarup Gupta
Dovish comments from Yellen helped global stocks post gains.
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.
Pfizer Xeljanz Label Expansion Application Accepted by FDA
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.